IP Library Granted Patent US 8,232,397
Granted Patent B2
US 8,232,397 · App. 12/586,855 · Granted Jul 31, 2012

Processes for the production of buprenorphine with reduced impurity formation

Assignee: Mallinckrodt LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,232,397
App. No.
12/586,855
Granted
Jul 31, 2012
Kind
B2
Abstract

The present invention provides process for the production of opiate alkaloids. In particular, the present invention provides processes for the production of buprenorphine or a derivative of buprenorphine that minimizes the formation of impurities.

Claims (41)

1. A process for the preparation of a compound of Formula (VII) according to the following reaction scheme:

wherein:

R is an alkyl or substituted alkyl;

R 1 is selected from the group consisting of an alkyl, a substituted alkyl, a cycloalkyl, and a substituted cycloalkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 10 , and {—}OR 10 ;

R 6 and R 7 are independently selected from the group consisting of hydrogen, a protecting group, hydrocarbyl, and substituted hydrocarbyl;

R 8 , R 9 , and R 10 are independently selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

M is selected from the group consisting of a metal cation having a charge of +1, and a metal cation group having a charge of +2;

X is oxygen; and

X 1 is a halogen;

the process comprising:

(a) contacting a compound of Formula (I) with a dienophile in the presence of a solvent comprising water to form a compound of Formula (II);

(b) contacting the compound of Formula (II) with an aprotic solvent and a catalyst that catalyzes hydrogen addition to form a compound of Formula (III);

(c) contacting the compound of Formula (III) with R 9 MgX 1 to form the compound of Formula (IV);

(d) contacting the compound of Formula (IV) with X 1 CN to form the compound of Formula (V);

(e) contacting the compound of Formula (V) with a hydrolysis agent to form the compound of Formula (VI); and

(f) contacting the compound of Formula (VI) with MCO 3 a catalytic additive, and R 1 X 1 , the amount of alkenyl impurity in R 1 X 1 being less than 0.15% by weight, and heating the reaction mixture to a temperature of less than 60° C. to form the compound of Formula (VII).

2. The process of claim 1 , wherein R, R 6 , R 7 , R 8 and R 9 are alkyl or substituted alkyl, and R 1 is cycloalkyl or substituted cycloalkyl.

3. The process of claim 2 , wherein R 2 , R 3 , R 4 , and R 5 are hydrogen.

4. The process of claim 1 , wherein R, R 6 , R 7 and R 8 are methyl, and R 1 is methylcyclopropyl.

5. The process of claim 1 , wherein R 9 is selected from tertiary butyl, alkyl, and substituted alkyl, provided that if R 9 is alkyl or substituted alkyl then X 1 is chloride or bromide.

6. The process of claim 1 , wherein in step (a) the solvent comprises alcohol, and from about 10% to 35% (v/v) of water; the dienophile is selected from the group consisting of methyl vinyl ketone, maleic anhydride, methyl acrylate, diethyl fumarate, benzoquinone, acetylene, 4-phenyl-1,2,4-triazolin-3,4-dione, and 2-methyl-propenal; and the reaction mixture is heated to a temperature of about 50° C. to about 100° C. for a period time that is sufficient for the conversion of a substantial portion of the compound of Formula (I) to the compound of Formula (II).

7. The process of claim 6 , wherein a seed material comprising a crystalline form of the compound of Formula (II) is added to the reaction mixture as the reaction mixture is cooled to a temperature of about 5° C.; the amount of α-epimer formed at C(7) is greater than about 99.5% by weight of the amount of compound of Formula (II), and the amount of β-epimer formed at C(7) is less than about 0.50% by weight of the amount of compound of Formula (II).

8. The process of claim 1 , wherein in step (b) the aprotic solvent comprises isopropyl acetate, the catalyst is a palladium catalyst adsorbed onto a carbon support, and the hydrogenation reaction is conduced at a temperature from about 65° C. to about 85° C.

9. The process of claim 8 , further comprising removal of at least a portion of the isopropyl acetate after the hydrogenation reaction is substantially complete followed by the addition of an alkane as the hydrogenation reaction is cooled to less than 20° C.

10. The process of claim 1 , wherein step (c) further comprises a reaction product that includes the compound of Formula (IV) and an amount of the compound of Formula (III) that is unreacted.

11. The process of claim 10 , comprising:

(a) quenching the reaction product of step (c);

(b) filtering the quenched reaction product of step (a) to form a filtrate comprising an amount of the compound of Formula (III) and an amount of the compound of Formula (IV); and

(c) recycling the filtrate of step (b) by combining the filtrate with the compound of Formula (III) and R 9 MgX 1 and repeating step 1(c).

12. The process of claim 11 , wherein the molar ratio of the compound of Formula (III) to R 9 MgX 1 is from about 1:1 to about 1:5; step 1(c) is conducted at a temperature of from about 15° C. to about 100° C. and in the presence of a solvent system comprising an aprotic solvent; the reaction of step 11(b) is cooled to a temperature of less than 20° C.; step 11(c) is repeated up to four times; and repeating step 11(c) four times increases the yield of the compound of Formula (IV) by at least 20% compared to when no recycling step 11(c) is performed.

13. The process of claim 1 , wherein step (e) further comprises a reaction product that includes the compound of Formula (VI) and an amount of the compound of Formula (VIb); and isolating the compound of Formula (VIb) and contacting it with a second hydrolysis to form additional amounts of the compound of Formula (VI), the compound of Formula (VIb) corresponding to the following structure:

wherein X, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as described in claim 1 .

14. The process of claim 13 , wherein the first and second hydrolysis agents are each a compound having a pKa of greater than about 12.0.

15. The process of claim 14 , wherein the molar ratio of the compound of Formula (VI) to the first hydrolysis agent is from about 1:9 to about 1:15; and the molar ratio of the compound of Formula (VIb) to the second hydrolysis agent is from about 1:5 to about 1:9.

16. The process of claim 15 , wherein R 6 , R 7 , R 8 and R 9 are alkyl or substituted alkyl, and R 1 is cycloalkyl or substituted cycloalkyl.

17. The process of claim 16 , wherein R 2 , R 3 , R 4 , and R 5 are hydrogen; and R 9 is tertiary butyl.

18. The process of claim 17 , further comprising contacting compound (VII) with an agent to form a salt of compound (VII).

19. The process of claim 1 , wherein the optical activity of the compound of Formula (II), (III), (IV), (V), (VI), or (VII) is selected from the group consisting of (+), (−), and combinations thereof; the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of may be RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

20. The process of claim 1 , wherein compound (VII) is (−)-buprenorphine.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR: BREDNS E. ALLEN. PLEASE CORRECT TO BRENDA E. ALLEN PREVIOUSLY RECORDED ON REEL 023395 FRAME 0359. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR: BREDNS E. ALLEN. PLEASE CORRECT TO BRENDA E. ALLEN. Recorded Nov 4, 2009
From: ALLEN, BRENDA E.; JARVI, ESA T.; KALOTA, DENNIS J.; MEYER, JAMES R.; TOMAZI, KEITH G.; MANNINO, ANTHONY; ORR, BRIAN
To: MALLINCKRODT INC.
Reel/Frame 023466/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: ALLEN, BRENDS E.; JARVI, ESA T.; KALOTA, DENNIS J.; MEYER, JAMES R.; TOMAZI, KEITH G.; MANNINO, ANTHONY; ORR, BRIAN
To: MALLINCKRODT INC.
Reel/Frame 023395/0359 →
Continuity (2)
Provisional Application 61194777 · Sep 30, 2008
Related Publication 20100087647A1 · Apr 8, 2010